Environmental Laboratory
Sweden calls for tighter EU environmental legislation
Jul 12 2011
Many new medicines that find their way on to the European market are produced in countries such as India.
The MPA is concerned about the potential damage that could be caused to human health if companies do not take environmental health more seriously.
A report published by the organisation stated that emissions from such manufacturing plants are unacceptable and improvements are "an urgent matter".
Members of the MPA want the EU to sanction rulings that force Indian firms to better control the production of certain products - particularly those that have been proven to have an adverse affect on human and animal wellbeing.
"First and foremost this concerns antibiotics, certain medicinal products with hormone-disrupting substances and substances that can constitute a risk to the environment [if] they are used and produced in large volumes," the report read.
Around 600 pharmacists and doctors work at the MPA, which is a government body and one of the EU's leading regulatory authorities.
Posted by Lauren Steadman
Digital Edition
AET 28.2 April/May 2024
May 2024
Business News - Teledyne Marine expands with the acquisition of Valeport - Signal partners with gas analysis experts in Korea Air Monitoring - Continuous Fine Particulate Emission Monitor...
View all digital editions
Events
Jul 10 2024 Birmingham, UK
Jul 21 2024 Cape Town, South Africa
Australasian Waste & Recycling Expo
Jul 24 2024 Sydney, Australia
Jul 30 2024 Jakarta, Indonesia
China Energy Summit & Exhibition
Jul 31 2024 Beijing, China